NTRA Key Statistics, Chart & Performance
The current stock price of NTRA is 238.285 USD. In the past month the price increased by 23.59%. In the past year, price increased by 42.34%.
NTRA Latest News, Press Relases and Analysis
NTRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.85 | 398.30B | ||
| AMGN | AMGEN INC | 15.49 | 182.45B | ||
| GILD | GILEAD SCIENCES INC | 15.24 | 154.82B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.69 | 108.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 902.81 | 60.83B | ||
| INSM | INSMED INC | N/A | 44.76B | ||
| BIIB | BIOGEN INC | 10.62 | 26.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.2 | 20.68B | ||
| INCY | INCYTE CORP | 15.9 | 20.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.23B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.06 | 15.03B |
Related stock screener links
About NTRA
Company Profile
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Company Info
NATERA INC
13011 Mccallen Pass, Building A Suite 100
Austin TEXAS 78753 US
CEO: Steve Chapman
Employees: 4424
Phone: 16502499090
NATERA INC / NTRA FAQ
What does NATERA INC do?
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 4,424 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Can you provide the latest stock price for NATERA INC?
The current stock price of NTRA is 238.285 USD. The price decreased by -0.22% in the last trading session.
Does NATERA INC pay dividends?
NTRA does not pay a dividend.
What is the ChartMill rating of NATERA INC stock?
NTRA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in NATERA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NTRA.
What is NATERA INC worth?
NATERA INC (NTRA) has a market capitalization of 32.89B USD. This makes NTRA a Large Cap stock.
Can you provide the upcoming earnings date for NATERA INC?
NATERA INC (NTRA) will report earnings on 2026-02-25, after the market close.
NTRA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NTRA. When comparing the yearly performance of all stocks, NTRA is one of the better performing stocks in the market, outperforming 91.99% of all stocks.
NTRA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to NTRA. No worries on liquidiy or solvency for NTRA as it has an excellent financial health rating, but there are worries on the profitability.
NTRA Financial Highlights
Over the last trailing twelve months NTRA reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -30.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.97% | ||
| ROE | -24.69% | ||
| Debt/Equity | 0.06 |
NTRA Forecast & Estimates
27 analysts have analysed NTRA and the average price target is 231.55 USD. This implies a price decrease of -2.83% is expected in the next year compared to the current price of 238.285.
For the next year, analysts expect an EPS growth of -32.78% and a revenue growth 26.21% for NTRA